Literature DB >> 27725588

Hepcidin.

Tomas Ganz1.   

Abstract

Hepcidin is an iron-regulating peptide hormone made in the liver. It controls the delivery of iron to blood plasma from intestinal cells absorbing iron, from erythrocyte-recycling macrophages, and from iron-storing hepatocytes. Hepcidin acts by binding to and inactivating the sole cellular iron exporter, ferroportin, which delivers iron to plasma from all iron-transporting cells. In a classical endocrine feedback system, hepcidin production is stimulated by plasma iron and iron stores. Reflecting a likely role of hepcidin in innate immunity, hepcidin is also induced by inflammation. Increased erythropoietic activity suppresses hepcidin, which leads to increased iron absorption and release of iron from stores, matching iron supply to increased demand. This suppression of hepcidin is in part mediated by erythroferrone, a hormone produced by erythropoietin-stimulated erythroblasts. Hereditary hemochromatosis is caused by hepcidin deficiency or resistance to hepcidin, and hepcidin deficiency also mediates the hyperabsorption of iron in β-thalassemia and other iron-loading anemias. Pathologically increased concentrations of hepcidin are seen in iron-refractory iron deficiency anemia, in anemia of inflammation, and anemia of chronic kidney disease where increased hepcidin limits the availability of iron for erythropoiesis. Its central involvement in a variety of iron disorders makes hepcidin an important target for diagnostic and therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27725588     DOI: 10.11406/rinketsu.57.1913

Source DB:  PubMed          Journal:  Rinsho Ketsueki        ISSN: 0485-1439


  5 in total

1.  [Expression and influencing factors of hepcidin in classical paroxysmal nocturnal hemoglobinuria].

Authors:  Y S Wang; H J Yao; L J Bo; Y P Zhao; Y L Zhang; F K Zhang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-10-14

2.  Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study.

Authors:  Keitaro Yokoyama; Masafumi Fukagawa; Takashi Akiba; Masaaki Nakayama; Kyoko Ito; Koji Hanaki; Myles Wolf; Hideki Hirakata
Journal:  Sci Rep       Date:  2019-06-20       Impact factor: 4.379

Review 3.  New Biomarkers of Ferric Management in Multiple Myeloma and Kidney Disease-Associated Anemia.

Authors:  Małgorzata Banaszkiewicz; Jolanta Małyszko; David H Vesole; Karolina Woziwodzka; Artur Jurczyszyn; Marcin Żórawski; Marcin Krzanowski; Jacek Małyszko; Krzysztof Batko; Marek Kuźniewski; Katarzyna Krzanowska
Journal:  J Clin Med       Date:  2019-11-01       Impact factor: 4.241

4.  Characterization of Erythroferrone in a Teleost Fish (Dicentrarchus labrax) With Two Functional Hepcidin Types: More Than an Erythroid Regulator.

Authors:  João V Neves; Carolina Barroso; Pedro Carvalho; Magda Nunes; José F M Gonçalves; Pedro N S Rodrigues
Journal:  Front Immunol       Date:  2022-04-08       Impact factor: 8.786

5.  Higher Hepcidin Levels in Adolescents with Obesity Are Associated with Metabolic Syndrome Dyslipidemia and Visceral Fat.

Authors:  Reyna Rodríguez-Mortera; Russell Caccavello; Ricardo Hermo; María Eugenia Garay-Sevilla; Alejandro Gugliucci
Journal:  Antioxidants (Basel)       Date:  2021-05-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.